COMMUNIQUÉS West-GlobeNewswire

Scilex Holding Company to Present Poster on ELYXYB® (celecoxib oral solution) at the 66th Annual Scientific Meeting of the American Headache Society (AHS) to be Held in San Diego, CA on June 13-16, 2024
13/06/2024
Up to 60% of patients with migraine do not sufficiently respond to triptans. Efficacy of celecoxib oral solution in participants with insufficient response to triptans for the acute treatment of migraine: pooled results [...]
Aeroflow Health Celebrates New Growth Milestones & Reshares its Commitment to Employee Well-Being
13/06/2024
On the Heels of its Sky High Growth Award from the Asheville Chamber of Commerce, Aeroflow Reflects on its Growth, Company Values and Emphasis on Employee Benefits ASHEVILLE, N.C., June 13, 2024 (GLOBE NEWSWIRE) -- [...]
NeuroStar Showcases Cutting-Edge Research at Clinical TMS Society Annual Meeting
13/06/2024
Early prediction of nonresponse abstract selected for oral presentation as a prestigious Top 4 Abstract at CTMSS 2024 MALVERN, Pa., June 13, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical [...]
Lisata Therapeutics Announces Full Enrollment of Pancreatic Cancer Cohort of CENDIFOX Trial
13/06/2024
Phase 1b/2a open-label trial in the U.S. of certepetide in combination with neoadjuvant FOLFIRINOX based therapies in pancreatic, colon and appendiceal cancers BASKING RIDGE, N.J., June 13, 2024 (GLOBE NEWSWIRE) -- [...]
Aphaia Pharma Completes Enrollment in Arm 2 of Phase 2 Trial in Individuals with Obesity
13/06/2024
Enrollment has been completed for the last four cohorts evaluating the contribution of circadian effects in weight loss treatment using Aphaia’s formulation Topline data anticipated in Q3 and Q4 2024 for Arm 1 and Arm 2 [...]
Sharps Technology Receives $30 Million Purchase Order for Prefillable Copolymer Syringes to be Manufactured at SC Facility
13/06/2024
Signed PO secures first 12 months of syringe product orders against Sharps and Nephron’s five-year, $200 million Syringe Sales Agreement. Current Asset Purchase Agreement closing timeline is on track for expected [...]
Replimune Announces $100 Million Private Placement Financing
13/06/2024
- Led by a life-sciences focused institutional investor, with participation from Redmile Group, RTW Investments, Boxer Capital and other institutional investors - - Financing follows strong primary analysis data from [...]
Intelligent Bio Solutions Implements Strategic Reorganization Plan to Support Global Growth Initiatives
13/06/2024
NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today [...]
TOMI Environmental Solutions Supports Partners and Customers to Combat Global Avian Influenza (H5N1) Bird Flu Outbreak
13/06/2024
FREDERICK, Md., June 13, 2024 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination utilizing its premier Binary Ionization [...]
Opus Genetics Announces $1.7 Million in Project-based Funding from the Foundation Fighting Blindness to Support Two Preclinical Programs
13/06/2024
$1M TRAP award to support preclinical safety study for gene therapy vector targeting rhodopsin- RHO-adRP Additional project and operational funding to support MERTK gene therapy IND-enabling studies RESEARCH TRIANGLE [...]
Umoja Biopharma Announces Publication in Blood Highlighting Successful Generation of In Vivo CAR T-cells in Non-Human Primate Modeling
13/06/2024
- First landmark, peer-reviewed publication of successful in vivo CAR T-cell data in an immune competent NHP model - - Data validate the VivoVec™ platform in a translationally relevant model and support its transition [...]
Dentsply Sirona Provides Update on June Investor Conference Participation
12/06/2024
CHARLOTTE, N.C., June 12, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that it is canceling its participation in the Goldman Sachs 45th Annual Global [...]
Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications
12/06/2024
NEW YORK, June 12, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving [...]
Cellectis dévoile une approche de thérapie génique non-virale pour traiter la drépanocytose dans Nature Communications
12/06/2024
NEW YORK, 12 juin 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique, qui utilise sa technologie pionnière d'édition de génome TALEN ® pour développer [...]
Connect Biopharma Announces New Leadership and Chair of the Board of Directors
12/06/2024
Industry leader Barry Quart, Pharm.D. appointed as Chief Executive Officer succeeding Zheng Wei, Ph.D., who will remain on the Board of Directors and serve as an advisor to assist with the transition Experienced life [...]
NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024
12/06/2024
PARIS and CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand [...]
NANOBIOTIX ORGANISE UNE DISCUSSION VIRTUELLE ENTRE EXPERTS SUR LE POTENTIEL DE NBTXR3 EN IMMUNOTHÉRAPIE DANS LE CANCER DE LA TÊTE ET DU COU ET D’AUTRES INDICATIONS LE 18 JUIN 2024
12/06/2024
PARIS et CAMBRIDGE, Mass., 12 juin 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ : NBTX – la « Société » ), société française de biotechnologie en phase de développement clinique avancé, pionnière des [...]
QIAGEN publishes 2023 sustainability report, highlighting progress on ESG goals and commitment to sustainable growth
12/06/2024
ESG commitments recognized as strategic business investments bringing value to stakeholders, including customers and employees // Environment: 15% reduction in Scope 1 and 2 emissions in 2023 through green energy [...]
Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
12/06/2024
SOUTH SAN FRANCISCO, Calif., June 12, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced that on June 10, 2024, it granted stock options to purchase an aggregate of 120,000 shares of [...]

Pages